BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ironwood Pharmaceuticals (IRWD) Costs Increase to Offset Revenue Upside - Wedbush
February 19, 2016 9:51 AM ESTWedbush analyst, David Nierengarten, is cautious on Ironwood Pharmaceuticals (NASDAQ: IRWD) as operating leverage remains elusive. No change to Neutral rating but the PT drops to $9 from $10.
IRWD reported 4Q15 Linzess US net sales of $129.7M, in-line with our estimate of $132M. Symphony Health Solutions recorded sales of $199.6M, implying a g-t-n of 35%, in line with last quarter. IRWD reported more than 585k scripts were filled in Q4,... More
Mizuho Securities Reiterates Buy Following Ironwood Pharma's (IRWD) Strong 4Q Results
February 19, 2016 9:30 AM ESTMizuho Securities reiterated a Buy rating and $15.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's 4Q earnings report. IRWD reported revenues of $53.3M, beating consensus estimates of $44.5M. EPS loss of ($0.09) also came in ahead of consensus' ($0.17). Management also issued... More
Leerink Partners Remains Sidelined After Ironwood Pharma's (IRWD) 4Q
February 19, 2016 7:22 AM ESTLeerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and cut the price target to $11.00 (from $12.00), following the company's 4Q earnings release. IRWD reported 4Q Linzess sales of ~$130m, coming in slightly below Leerink's estimate of ~$131m. Collaborative revenues of ~$53m were in line with estimates. IRWD plans to progress IW-1701 and IW-1973 into... More
Ironwood Pharma (IRWD) Tops Q4 EPS by 7c
February 18, 2016 4:07 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.10), $0.07 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $53.3 million versus the consensus estimate of $45.55 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... MoreIronwood Pharma (IRWD) to Initiate Phase Ib Study of IW-1701 Following Positive Top-Line Phase Ia Data
February 18, 2016 8:23 AM ESTIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced positive top-line data from a Phase Ia study of IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator from Ironwoods vascular and fibrotic disease platform. In the study, IW-1701 demonstrated the expected cardiovascular pharmacodynamic effects, proof of mechanism for sGC stimulation, a dose range... More
